Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab

BACKGROUND: Metastatic TNBC (mTNBC) has a poor prognosis and few treatment options. The anti-PD-L1 antibody atezolizumab demonstrated clinical activity in mTNBC patients with PD-L1-positive tumor-infiltrating immune cells. The current study describes the tumor immune microenvironment (TiME) and geno...

Descripción completa

Detalles Bibliográficos
Autores principales: Molinero, Luciana, Li, Yijin, Chang, Ching-Wei, Maund, Sophia, Berg, Maureen, Harrison, Jeanne, Fassò, Marcella, O’Hear, Carol, Hegde, Priti, Emens, Leisha A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6813065/
https://www.ncbi.nlm.nih.gov/pubmed/31647026
http://dx.doi.org/10.1186/s40425-019-0740-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6813065/
https://www.ncbi.nlm.nih.gov/pubmed/31647026
http://dx.doi.org/10.1186/s40425-019-0740-8

Ejemplares similares